Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × marizomib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 5 Recurrence 3 Glioblastoma 3 Lymphoma 2 Glioma 2 Brain Neoplasms 2 Solid Tumor 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia 1 Gliosarcoma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 150 Gemcitabine 135 Paclitaxel 128 Carboplatin 118 Bevacizumab 110 Surveys and Questionnaires 97 Docetaxel 95 Cisplatin 94 Cyclophosphamide 93 Exercise 89 Blood Specimen Collection 85 Nivolumab 82 Fluorouracil 75 Capecitabine 73 Dexamethasone 70 Radiotherapy 69 Irinotecan 62 Standard of Care 59 Pemetrexed 59 Oxaliplatin 57 Leucovorin 54 Drug Therapy 54 Cetuximab 48 Erlotinib Hydrochloride 46 atezolizumab 44 Sorafenib 44 Interviews as Topic 41 Doxorubicin 41 Ipilimumab 38 Magnetic Resonance Spectroscopy 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04341311 2024-02-15

DIPG

Dana-Farber Cancer Institute

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡